Globus Medical (NYSE:GMED) Director Stephen Zarrilli Sells 25,000 Shares

Globus Medical, Inc. (NYSE:GMED) Director Stephen Zarrilli sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares in the company, valued at approximately $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Globus Medical Stock Up 2.4%

Shares of NYSE:GMED opened at $88.48 on Thursday. The company has a market cap of $11.88 billion, a PE ratio of 22.63, a P/E/G ratio of 1.39 and a beta of 0.95. Globus Medical, Inc. has a fifty-two week low of $54.15 and a fifty-two week high of $101.40. The firm has a 50-day simple moving average of $80.35 and a 200 day simple moving average of $84.80.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The firm had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. Globus Medical’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts forecast that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Stifel Nicolaus decreased their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research note on Wednesday, July 8th. Royal Bank Of Canada cut their price objective on Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Truist Financial decreased their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Piper Sandler dropped their price target on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research report on Monday, June 15th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Globus Medical has an average rating of “Moderate Buy” and an average target price of $101.77.

Hedge Funds Weigh In On Globus Medical

Hedge funds have recently modified their holdings of the stock. Elevation Wealth Partners LLC boosted its position in shares of Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 305 shares during the period. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the third quarter worth about $26,000. EverSource Wealth Advisors LLC increased its position in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares during the period. Finally, Parallel Advisors LLC raised its position in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.